CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1×1 investor meetings at the JMP Securities Hematology and Oncology Summit.
JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics.…
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2025) - Custom Health, Inc. ("Custom Health"), a…
CHICAGO, Ill., May 30, 2025 /PRNewswire/ -- Vaniam Group™, a leader in medical communications, is…
PEARLAND, Texas, May 30, 2025 /PRNewswire/ -- Cornerstone Specialty Network ("Cornerstone"), a leading provider of…
Youth-led solutions support healthier tech use and peer wellness SACRAMENTO, Calif., May 30, 2025 /PRNewswire/…
Sanjay Gupta from Imbed Biosciences Inc. Featured in The Wall Street Journal as a Distinguished…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
